 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Bio-Technology General Corp.
 |
Bio-Technology General Corp. |
 |
 |
 |
PROFILE |
 |
Bio-Technology General develops and markets genetically engineered and other pharmaceuticals. The firm's key products, sold in select markets worldwide, include OXANDRIN (more than half of product sales), a treatment for weight loss due to trauma, surgery, or disease (mainly HIV); BIO-TROPIN, a growth hormone for children; DELATESTRYL, an injectable testosterone for delayed puberty; and Mircette, an oral contraceptive. Drugs in development include treatments for asthma, cancer, diabetes, and gout. Bio-Technology General develops generic drugs for Teva Pharmaceuticals. Israeli subsidiary Bio-Technology General (Israel) performs much of the company's R&D. Nearly 40% of the firm's sales are outside the US.
COMPETITION |
 |
Barr Laboratories, Inc. (BRL)
Genentech, Inc. (DNA)
Warner Chilcott Public Limited Company (dossier)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 67.20
1-Yr. Sales Growth: 2.1%
Employees: 325
Revenue per employee: $206,769.23
KEY PEOPLE |
 |
Sim Fass
CEO
Yehuda Sternlicht
CFO
CONTACT INFO |
 |
70 Wood Ave. South
Iselin, NJ 08830
US
Phone: 732-632-8800
Fax: 732-632-8844
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |